Langlois is pleased to report that its client LSL Pharma Group has been listed on the TSX Venture Exchange (“TSXV”) following a reverse takeover (“RTO”) with Iledor Exploration Corporation.
The closing follows a major corporate restructuring and a series of complex transactions a share consolidation, a $47.7 million shares and rights exchange, and a private placement consisting of shares and warrants totalling $8.2 million – all led by the Langlois securities team. iA Private Wealth Inc. acted as an independent agent in connection to the financing.
This RTO demonstrates the breadth of our lawyer’s expertise in the areas of Securities Law and stock exchange listings. The transaction was led by Pierre-Hubert Séguin and included Éric Archambault, Sylvain Aird, Sarah Ettedgui, Angelica Clément, François-Alexandre Marois, Anne-Laure Damhet, Angela Kosciuk, Félix Bernard, Philippe Blais, Valérie Côté, Delphine Grou, Naya Hachem, Catherine Vaillancourt and Sophie Sigouin Corbeil.
About LSL Pharma Group
The LSL Group is a Canadian integrated pharmaceutical company specializing in the development, manufacture and distribution of high-quality natural health products and dietary supplements in solid dosage forms as well as high quality sterile ophthalmic pharmaceutical products.
Read the LSL Pharma Group press release
T +1 438 844-7800
M +1 514 951 0553